YouSaid · the spoken record
Ian Murray
Lines from Political Thinking with Nick Robinson have been withdrawn from this page while we check who is speaking. See the correction.
On the record 2010–2026
hansard
This is everything the corpus holds for Ian Murray. It is not everything they have said on the record.
Every line below is reproduced as it was said and credited to the record it came from, and links to that record wherever it can be linked. Nothing here is summarised or generated. Directory · Search · Corrections
“With the actions under way across discovery, research, validation, regulatory decision making and governance, and indeed the money to support some of that, delivery is being supported through co-ordinated action across the Office for Life Sciences, NC3Rs, UKRI bodies and regulators. The MRC has launched the £20 million fund to which I referred, and Innovate UK and NC3Rs continue to work in partnership to advance development. In March 2026, the MHRA published new guidance setting out how applications for medicines that use non-animal methods will be assessed and fast-tracked. A lot of the strategy has therefore already been put in place, but the strategy cannot be just words; it needs action as well. Let me run through some of the challenges and questions raised by hon.”
House of Commons27 April 2026Contains Parliamentary information licensed under the Open Parliament Licence v3.0Source ↗
“We do not disagree with the principle of Herbie’s law; indeed, that is what the strategy is trying to achieve. The challenge for the Government, of course, is to balance that against what is achievable and what can be validated, not just in the UK but across the international community. We want this country to be a world leader in eliminating animal research, and it is pretty clear, on the front page of the strategy, that we wish to take those 26 actions on. Let me continue as that will help to answer the hon. Member’s question. The hon. Member for Yeovil (Adam Dance) challenged us to say what the strategy has delivered so far. We have moved from commitments towards trying to deliver.”
House of Commons27 April 2026Contains Parliamentary information licensed under the Open Parliament Licence v3.0Source ↗
“The strategy does therefore have defined end points, where they can be defined. Basket three covers complex end points and long-term aims. By the end of 2035, we aim to include alternative methods and regulations for endocrine disruption tests—I do not know what that means, but maybe one of the vets in the Chamber can tell us. Those aims are not on a statutory footing, but they are Government commitments. They are gateways that we want to go through with the three baskets approach.”
House of Commons27 April 2026Contains Parliamentary information licensed under the Open Parliament Licence v3.0Source ↗
“We will write to her on the finer details about whether we have those 22 inspectors in place. Let me go into why we would not put Herbie’s law on a statutory footing. In line with international practice, we are using the three baskets approach to group animal tests and prioritise their replacements—this is mainly about dogs. Basket one covers areas where there is a mature replacement tech: for example, the strategy aims by the end of 2026—this year—to use only alternative methods for skin irritation testing. Basket two covers areas where there are medium-term replacements: we aim to replace the use of fish acute toxicity tests for chemicals regulated by REACH, the regulation on the registration, evaluation, authorisation and restriction of chemicals, by the end of 2028.”
House of Commons27 April 2026Contains Parliamentary information licensed under the Open Parliament Licence v3.0Source ↗
“Who has the cat called Chairman Meow, then? It must be somebody else. My hon. Friend was right to mention the Competition and Markets Authority investigation into vet costs. We want to achieve our manifesto commitment on that issue; it was a very clear part of our manifesto and we all want to see the same outcomes from that. The hon. Member for Yeovil mentioned AI and asked us about the action so far, which I have run through. In response to my hon. Friend the Member for Newport West and Islwyn (Ruth Jones), we agree with the principle of Herbie’s law. We cannot set arbitrary timelines for things that we may not be able to achieve, but we have set some strong ones already, including the 35% reduction by 2030. If we can go faster and further, of course we will; it will depend on whether we can get validated scientific research in place.”
House of Commons27 April 2026Contains Parliamentary information licensed under the Open Parliament Licence v3.0Source ↗
“We will keep driving the shift to validated alternative methods wherever possible, while maintaining the robust protections that keep people, animals and the environment safe in the meantime. I thank Members once again for their insightful contributions to the debate; I am sure we will have many more in the future, and I look forward to working together as the strategy progresses.”
House of Commons27 April 2026Contains Parliamentary information licensed under the Open Parliament Licence v3.0Source ↗
“However, an immediate prohibition would undermine the UK’s ability to test and regulate new medicines and vaccines for humans and, indeed, for the animals themselves. We would be unable to meet our international regulatory requirements for drug safety testing, which would prevent virtually all first-in-human trials in the UK from happening, compromise our capacity to respond rapidly to future health threats, result in slower access to new treatments for UK patients and slow the innovation required to remove animal testing altogether. That is the key challenge that we are seeking to achieve with the strategy. We want a future where animals are used only in very exceptional circumstances and we are acting as fast as we can to get there through the “Replacing animals in science” strategy and its delivery.”
House of Commons27 April 2026Contains Parliamentary information licensed under the Open Parliament Licence v3.0Source ↗
“Animal studies are only one part of a layered system that screens out unsafe or ineffective substances before they ever reach volunteers and patients. Animal testing is required by all global medicines regulators, including the MHRA; that is another international issue we have to resolve. Although the MHRA does not require all medicines to be tested on two species, safety testing in a second species is required for most drugs, with dogs being one of the species that can be used. The key proposal in the petition calls for the end of testing on dogs and other animals for the development of products for human use. None of us wants dogs to be used in research, despite how carefully animal welfare is regulated in this country.”
House of Commons27 April 2026Contains Parliamentary information licensed under the Open Parliament Licence v3.0Source ↗
“For now, animal testing and research plays an important role in supporting the development of new medicines and cutting-edge medical technologies for humans and animals—for example, the development of the covid-19 vaccine. Many Members have mentioned failure rates. Animals are used to assess how potential new medicines affect biological systems, ensuring that drugs are safe and effective before human trials. The petition points out that 90% of drugs that appear safe and effective in animals do not go on to receive FDA approval. However, to say that 92% of drugs fail in human trials despite being tested on animals is to ignore all those candidate drugs that are tested on animals and found not to be suitable to progress to human trials. That is the issue that we are trying to resolve.”
House of Commons27 April 2026Contains Parliamentary information licensed under the Open Parliament Licence v3.0Source ↗
“The UK has some of the most stringent regulations in the world governing how animals are bred, housed and cared for, with legally enforceable standards, regular announced and unannounced inspections, and a clear requirement to minimise pain, suffering and distress. The use of animals in science is highly regulated. All establishments are required to have dedicated individuals, including veterinary surgeons, with legal responsibilities for the care and welfare of animals, and an ethical review body that reviews any proposals for the use of animals and promotes the three Rs of animal use. The reality is that the technology is not yet advanced enough for alternative methods to replace the use of animals completely.”
House of Commons27 April 2026Contains Parliamentary information licensed under the Open Parliament Licence v3.0Source ↗
“That Act specifies that animals can only be used in science for specific, limited purposes where there are no alternatives, where the number of animals used is the minimum needed to achieve the scientific benefit, and where the potential harm to animals is limited to the absolute minimum. Those requirements are known as the three Rs: replacement, reduction and refinement, as we have discussed. Dogs are a specifically protected species under ASPA. Projects must justify why animals are needed, why dogs specifically are needed, and why the numbers and procedures are necessary. Projects are only authorised where that justification is robust. The e-petition rightly mentions the conditions in which dogs are kept, and I want to address those claims—not to dismiss them, but to show that the regulatory system in the UK works.”
House of Commons27 April 2026Contains Parliamentary information licensed under the Open Parliament Licence v3.0Source ↗
“There has been a lot done in this area; many Members have mentioned the word “pace”, and that is what we want to see, but the previous Government took a number of actions. Is a 35% reduction by 2030 achievable? We think it is. Many would say that that is not ambitious enough and some would say that it is too ambitious, but we do want to achieve it. That is why the strategy is in place, and why money is a key part of it. Using animals in science requires us to adhere continually to the highest possible standards of animal welfare. That is reflected in the UK’s world-leading, robust regulation of the use of animals in science through the Animals (Scientific Procedures) Act 1986.”
House of Commons27 April 2026Contains Parliamentary information licensed under the Open Parliament Licence v3.0Source ↗
“While we have testing in this country and regulate it to those standards, we should be making sure that the standards are met, notwithstanding all the issues that have been raised by Members today. However, there is a real danger that if we were to cut that off now, without alternatives in place, it would go overseas—an issue that the shadow Minister, the hon. Member for Bromley and Biggin Hill (Peter Fortune), also raised. We will have to come back to the hon. Member for Winchester on dual licensing for veterinary use. There is an issue with the way in which animal testing works with regard to the licensing arrangements that he set out. Animal testing is also used for the veterinary side of medicines and advancements in technology, and we must be cognisant of that. I appreciate the tone in which the shadow Minister spoke.”
House of Commons27 April 2026Contains Parliamentary information licensed under the Open Parliament Licence v3.0Source ↗
“Member for Winchester (Dr Chambers), listed the advances in life science innovation; that is tremendous progress, but we need to go further and faster to move away from animal testing. He posed that challenge and we agree with him. He also made the important point that we have a strict regulatory environment for animal testing in this country. I will come on to that in my conclusion, but it is one of strictest in the world, and rightly so. The hon. Member rightly challenged us by pointing out the danger that if we were to cut animal testing off now, it would go overseas, and in that case we would see a whole raft of additional animals suffering in places that do not have the same standards. That is not to diminish the issue.”
House of Commons27 April 2026Contains Parliamentary information licensed under the Open Parliament Licence v3.0Source ↗
“Friend the Member for Dunstable and Leighton Buzzard (Alex Mayer) is right that replacing animals in testing is the right thing to do and that the public want to see action. We agree; that is why we are taking action. The strategy should seed that innovation. It is not just about the Government saying, “This is what we want to achieve.” Hopefully, the industry and innovation will seed that through. We have seen that with other advancements, such as the ban on cosmetics testing that my hon. Friend talked about. Hopefully, that will seed industry to move forward and find innovative ways through, backed by the Government strategy. The Liberal Democrat spokesperson, the hon.”
House of Commons27 April 2026Contains Parliamentary information licensed under the Open Parliament Licence v3.0Source ↗
“We will write to my hon. Friend with the details on those individual projects—the regulations are run by the Home Office, so I will write to her on those three specific issues and make sure that everyone in the Chamber has a copy. My hon. Friend the Member for North East Hertfordshire (Chris Hinchliff) said that the scale of the suffering prevented should overwhelmingly outweigh the suffering involved in testing. I think we would all agree with that. That is exactly the proportionate way in which we need to look at the issue. It is undeniable that huge pharmaceutical and medical progress has been made on the back of animal testing—the covid vaccine was a good example of alleviating suffering—but he is right to challenge us on that moral issue. That is why the strategy is in place. My hon.”
House of Commons27 April 2026Contains Parliamentary information licensed under the Open Parliament Licence v3.0Source ↗
“Ensuring the safe use of UK data is a priority for the Government. I commend this statement to the House.”
House of Commons23 April 2026Contains Parliamentary information licensed under the Open Parliament Licence v3.0Source ↗
“This has been an unacceptable abuse of the UK Biobank charity’s data, and an abuse of the trust that participants rightly expect when sharing their data for research purposes. The Government take the incident extremely seriously, which is why we have acted rapidly to support the UK Biobank charity in its response and why I wanted to update the House at the earliest opportunity. The Government will soon be issuing new guidance on control of data from research studies. I take this opportunity once again to urge all businesses and charities to ensure that that their systems and data-sharing processes are as secure as possible. We wrote to businesses last week about the cyber-security tools available to them—for free—from the Government and the steps they should take to maximise security.”
House of Commons23 April 2026Contains Parliamentary information licensed under the Open Parliament Licence v3.0Source ↗
“In summary, and to be clear to the House and to those people affected, the charity has assured us that the data did not contain anybody’s names, addresses or contact details. It includes only data of people who have explicitly opted in to be part of the Biobank. Those are people who have given their explicit consent that this data can be used, in the knowledge that it will be shared with researchers globally. Participants have done a great service to the people of this country, and human health globally, through their participation. For example, valuable research is being carried out at McGill University in Canada into chronic pain, which afflicts millions of people here in the UK. We expect UK Biobank to remain one of the leading health research resources.”
House of Commons23 April 2026Contains Parliamentary information licensed under the Open Parliament Licence v3.0Source ↗
“Officials have been in regular contact with UK Biobank since the Government were made aware of the issue on Monday. I personally spoke to the chief executive and chair last night, alongside the Minister of State for Science and the Minister for Health Innovation and Safety. We have received assurances that the charity will conduct a rapid board-level review of the safeguards in place for accessing its data. As I mentioned, in the short term, Biobank will suspend downloads from its platform. That is until a new system is brought in to control analysis downloads to approved researchers and will significantly enhance data access controls and safeguards. We have advised the chair and chief executive of Biobank to write to all participants as soon as possible to ensure that they are aware of what has happened.”
House of Commons23 April 2026Contains Parliamentary information licensed under the Open Parliament Licence v3.0Source ↗
“Secondly, we ensured that the Biobank charity revoked access to the three research institutions identified as the source of the information. Thirdly, we have asked that the Biobank charity pauses further access to its data until it has put in place a technical solution to prevent data from its current platform from being downloaded in this way again. I can confirm to the House that this pause is now in place. UK Biobank has also referred itself to the Information Commissioner’s Office. We are still working with Biobank to ascertain from it the specific detail of what has happened. We have asked it to investigate how this data ended up for sale online as a priority, but I wanted to ensure that the House was aware of the incident and the action that the Government are taking.”
House of Commons23 April 2026Contains Parliamentary information licensed under the Open Parliament Licence v3.0Source ↗
“I want to reassure the House up front, however, that Biobank has advised that this data did not contain participants’ names, addresses, contact details or telephone numbers. The Government have spoken to the vendor today and they do not believe that there were any purchases from the three listings before they were taken down. Once the Government were made aware of the situation, we took immediate action to protect participants’ data. First, we worked with Biobank, the Chinese Government and the vendor to ensure that the three listings that UK Biobank informed us included participant data had been removed. I want to thank the Chinese Government for the speed and seriousness with which they worked with us to help remove the listings and the ongoing work to remove any further listings.”
House of Commons23 April 2026Contains Parliamentary information licensed under the Open Parliament Licence v3.0Source ↗
“We are all grateful to those individuals who are part of this landmark study that is so important for all of our health. On Monday 20 April, the UK Biobank charity informed the Government that it had identified that its data had been advertised for sale by several sellers on Alibaba’s e-commerce platforms in China. Biobank told us that three listings that appeared to sell UK Biobank participation data had been identified. At least one of the three datasets appeared to contain data from all 500,000 UK Biobank volunteers. Additional listings offered support for applying for legitimate access to UK Biobank data or analytical support for researchers who already have access to the data.”
House of Commons23 April 2026Contains Parliamentary information licensed under the Open Parliament Licence v3.0Source ↗
“With permission, Madam Deputy Speaker, I will make a statement about the use of UK Biobank data. UK Biobank is a non-profit charity, independent of Government. The Biobank brings together data, kindly donated by its volunteer participants, that is shared with accredited researchers globally to make significant scientific discoveries that improve patient health. That includes discovering genes that affect the risk of heart disease or cancer, identifying new ways of predicting dementia, identifying early warning signs for cancers, understanding immunity to covid-19, and work towards earlier detection of Parkinson’s. It is one of the most successful and important studies of its type, and it continues to benefit patients in the UK and around the world.”
House of Commons23 April 2026Contains Parliamentary information licensed under the Open Parliament Licence v3.0Source ↗
“Secondly, although the three institutions are Chinese in this particular instance, the Chinese Government and Alibaba have been very proactive in helping us, through the British embassy in Beijing, to take down and whack-a-mole anything else that comes up, and they are currently going through that process. Yale University had its accreditation suspended for a breach of data, so this is not a country-specific issue. It just so happens that, in this particular case, the three institutions were Chinese. I think that answers the shadow Minister’s questions.”
House of Commons23 April 2026Contains Parliamentary information licensed under the Open Parliament Licence v3.0Source ↗
“The system also allows people—although, contractually, accredited organisations are not supposed to do this—to download datasets. We understand from Biobank that what has probably happened is that the three institutions have downloaded the datasets themselves. As yet, we are unclear as to how those datasets ended up on the website, but UK Biobank, along with institutions and organisations attached to the Government, is working through that at the moment. The hon. Gentleman asked for reassurance that Russia, Iran and North Korea are not accredited, and I understand from UK Biobank that they are not. He also mentioned hostile actors. UK Biobank is very strict about who has access, because there is an accreditation process.”
House of Commons23 April 2026Contains Parliamentary information licensed under the Open Parliament Licence v3.0Source ↗
“They have been immediately banned from the platform, and that will be permanent. The Biobank only works with accredited organisations, institutions and individual academic researchers, and the accreditation system is there to make sure that those using it are doing so for valid purposes. It has been running since 2012 and has been used for hundreds of thousands of different analyses. It works incredibly well and will continue to do so. Let me explain how the system works and where the problem has arisen. In 2024, the system was changed from Biobank issuing datasets to accredited organisations and academic researchers to having all the information on the Biobank platform. When people access the data, they do their analysis and then download it.”
House of Commons23 April 2026Contains Parliamentary information licensed under the Open Parliament Licence v3.0Source ↗
“I can give an indication of some of the characteristics that are potentially in UK Biobank datasets, which include gender; age; month and year of birth; assessment centre data; attendance date; socioeconomic status; lifestyle habits; measures from biological samples such as haematology and biochemistry—this is the kind of stuff that has been detected—online questionnaires data; sleep; diet; work environment; mental health, and health outcomes data. The shadow Minister asked whether there are identifiers for individuals. There are not, but it would be wrong for me to give 100% assurance—and UK Biobank cannot do so—that someone could not be identified from the data. However, it would have to be used in a very advanced way in order to do that. The hon. Gentleman asked about the three institutions.”
House of Commons23 April 2026Contains Parliamentary information licensed under the Open Parliament Licence v3.0Source ↗
“I thank the shadow Minister for the way in which he has approached this matter—indeed, with his expertise as a former COO of a tech company. Let me answer his questions directly. As we understand it—this is from UK Biobank, which is not a Government organisation, but an independent charity—UK Biobank cannot be entirely sure about the data that was included, because it was taken down from the Alibaba websites. However, we do know that there is no personal data in it, in terms of identifiers.”
House of Commons23 April 2026Contains Parliamentary information licensed under the Open Parliament Licence v3.0Source ↗
“We should encourage the public to make sure that they can volunteer their data, so that the health of all of us is improved as a result.”
House of Commons23 April 2026Contains Parliamentary information licensed under the Open Parliament Licence v3.0Source ↗
“My hon. Friend makes an incredibly important point. I will say from the Dispatch Box that we should encourage more participation in UK Biobank. It is a global leader in research and is funded by the Wellcome Trust and the Medical Research Council. It also receives significant funding from Cancer Research UK, the British Heart Foundation and the National Institute for Health and Care Research. That shows the breadth of research that it does on all the key diseases that we suffer from in this country, and it is resolving some of these problems. Chinese researchers are making significant progress on diseases such as Alzheimer’s. Biobank is a global platform, and it is very much welcomed as a research resource.”
House of Commons23 April 2026Contains Parliamentary information licensed under the Open Parliament Licence v3.0Source ↗
“It is because journals demand source data before publication in order to reduce fraud that the source data was included in some journal articles that linked directly to the source data on UK Biobank. Again, it was not a leak; it is about the way in which researchers used data incorrectly.”
House of Commons23 April 2026Contains Parliamentary information licensed under the Open Parliament Licence v3.0Source ↗
“I cannot recall whether the statement includes an apology, but we will take that back to Biobank—I am sure it is watching this statement. The Information Commissioner’s Office will also be involved, because this issue relates to data. Biobank has referred this incident to the ICO, and we will work very closely with it. I emphasise that we take this matter extremely seriously. We came to the House at the first available opportunity this morning, before the release from Biobank had gone out, to make sure that Members could reassure the volunteers and also see how seriously we take this issue. The hon. Lady referred to an article in The G uardian .”
House of Commons23 April 2026Contains Parliamentary information licensed under the Open Parliament Licence v3.0Source ↗
“The three Chinese organisations have been found to have done that, which is why they have been suspended from the site. This was not a leak as such. How that data has got from those institutions on to the Alibaba website is still to be concluded, but this was not a leak of data or a cyber-attack. This was a legitimate download of legitimate data by a legitimately accredited organisation, which is why we should not use the word “leak” for the purposes of reassuring the volunteers who put their data into the system. Let me answer the hon. Lady’s question about what has been done and what the Government have asked Biobank to do. I reiterate that the whole system has been paused, and the board has taken actions to write to all participants; in fact, there is a statement on Biobank’s website.”
House of Commons23 April 2026Contains Parliamentary information licensed under the Open Parliament Licence v3.0Source ↗
“I thank the Liberal Democrat spokesperson for the way in which she has dealt with this issue. I echo her thanks to all the volunteers—not only those who give their sensitive data to UK Biobank for critical purposes, but all the volunteers who give data for all research purposes. The Liberal Democrat spokesperson used the word “leak”, but this was not a leak; it was a legitimate download by a legitimately accredited organisation. We have identified a problem with the UK data bank system, in the sense that accredited users have used the system to analyse data sources and then download their results from that analysis, but the system has not prevented them from also downloading the source data. It is that downloaded source data that is against the terms of use for accredited organisations.”
House of Commons23 April 2026Contains Parliamentary information licensed under the Open Parliament Licence v3.0Source ↗
“UK Biobank has assured us over the past 24 hours that it is looking for a technical fix, which should happen relatively shortly, and we will hold it to that. To show that we are taking the situation as seriously as it should be taken, we have insisted as a Government that UK Biobank should pause all access to, downloads from and use of the system until the fix comes into place. I do not know the exact figures of usage, but across the globe there are somewhere in the region of more than 16,000 researchers using this resource, because it is so valuable. We should thank them for doing that and ensure that they have full access to UK Biobank in the safe way in which it should be used as soon as possible.”
House of Commons23 April 2026Contains Parliamentary information licensed under the Open Parliament Licence v3.0Source ↗
“Gentleman saw some of the advances being made, particularly on Alzheimer’s, he would know that we are working very closely with the research community across the world, from all countries. As I said to the shadow Minister, the previous suspension of accreditation was for Yale in the United States for misuse of data. Participants know that this research is used globally, and it is right that it is used globally for the advancement of us all. Banning researchers from the site would not be the way in which to advance the outcomes of UK Biobank.”
House of Commons23 April 2026Contains Parliamentary information licensed under the Open Parliament Licence v3.0Source ↗
“I do not think the tone of the hon. Gentleman’s question fits the seriousness of this issue. We are yet to get a conclusion from UK Biobank on what the process looked like for the three institutions that have been identified as downloading some datasets to transfer them to the seller, and we will update Members when we are clear on that. UK Biobank has told us quite clearly that that is what has happened. There are thousands of Chinese researchers working every day on data from UK Biobank and other datasets from across the world, and they have been doing that since 2012 safely and securely. The issue here is that a loophole in the system has allowed datasets to be downloaded alongside the analytical research. If the hon.”
House of Commons23 April 2026Contains Parliamentary information licensed under the Open Parliament Licence v3.0Source ↗
“To echo the words of the shadow Minister, it has dealt with the issue transparently, and we welcome that—that is what is required in these kinds of circumstances.”
House of Commons23 April 2026Contains Parliamentary information licensed under the Open Parliament Licence v3.0Source ↗
“Significant undertakings were given by the chair and board of UK Biobank this week. They have answered all the questions and worked very closely with the Government, the British embassy in Beijing and the Chinese Government to ensure that this instance is resolved as quickly as possible. They have immediately identified the loopholes that enabled the download of the data from the institution, and they are carrying out mitigation work to ensure that that cannot happen again and to tighten up the system. That should happen within weeks, but in the meantime the UK Government insisted that all access to and downloads from it be paused, and the entire system was paused to allow that work to happen. I pay tribute to UK Biobank for the swiftness with which it has done that.”
House of Commons23 April 2026Contains Parliamentary information licensed under the Open Parliament Licence v3.0Source ↗
“I understand from UK Biobank and from officials that they have been in talks with the pharmaceutical industry and researchers in the field to see whether that would cause a problem, and as long as this situation is temporary, it should not. They will technically be affected in the short term until access is fully recovered.”
House of Commons23 April 2026Contains Parliamentary information licensed under the Open Parliament Licence v3.0Source ↗
“I pay tribute to the Belfast universities and the way in which they have advanced research. As has already been mentioned, tens of thousands of individual accredited researchers use UK Biobank regularly, as do thousands of institutions across the globe. We need to ensure that the system is safe, so that volunteers participating in the system can be assured that their data is safe and secured, and that is why it has been paused. The hon. Gentleman challenges me on whether Belfast universities have been affected by this issue. They will be affected by it in the short term, because there is currently no access to the system, but we hope that that will be resolved.”
House of Commons23 April 2026Contains Parliamentary information licensed under the Open Parliament Licence v3.0Source ↗
“Yes, I can give that assurance. This Government are giving UK Biobank all the support that it requires to resolve the immediate issue and in the short term to get the system back up and running in as secure a way as possible. Let me echo that participants in UK Biobank have done a great service to the people of this country and around the world. We owe it to them to be transparent and secure, and to ensure that their data is not only safe but advancing UK and worldwide medical research for the benefit of everyone.”
House of Commons23 April 2026Contains Parliamentary information licensed under the Open Parliament Licence v3.0Source ↗
“We wrote to those organisations last week to inform them that those tools were available, and I continue to echo to all businesses, institutions and organisations that they should get involved in ensuring that they are as cyber-secure as possible. We are only as secure as the weakest, and we all have to be as secure as we possibly can be.”
House of Commons23 April 2026Contains Parliamentary information licensed under the Open Parliament Licence v3.0Source ↗
“In a previous question, my hon. Friend said that Harlow Town were the Man City of non-league football. May I simply suggest that he is the Man City of speaking in this Chamber in terms of the quality and regularity of his contributions? That may be challenged by the hon. Member for Strangford (Jim Shannon)—let us look at the data. I echo what my hon. Friend said in his question, because it is really important for us to impress on the public that data is secure and safe. This Government take that incredibly seriously, not just in the legislation being passed, which he has been a part of, but in the cyber-security tools available for free from this Government to businesses, organisations and institutions right across the country.”
House of Commons23 April 2026Contains Parliamentary information licensed under the Open Parliament Licence v3.0Source ↗
“I am happy to meet the hon. Gentleman and the local authority to discuss what more we can do for Eastbourne bandstand.”
House of Commons16 April 2026Contains Parliamentary information licensed under the Open Parliament Licence v3.0Source ↗
“We are committed to ensuring the UK remains the world’s leading destination for film and television production. That ambition sits at the core of the Government’s industrial strategy and the creative industries sector plan, which recognises the sector’s strength as a driver of growth. Every single best visual effects Oscar nominee this year had work done in UK studios, including Bournemouth’s own Outpost VFX for its work on “Sinners”.”
House of Commons16 April 2026Contains Parliamentary information licensed under the Open Parliament Licence v3.0Source ↗
“We understand and acknowledge the significant implications for the sector of various pressures at the moment, but there is £10 million being invested in the National Film and Television School to expand apprenticeships and £25 million of funding for five new CoSTAR—Convergent Screen Technologies and performance in Realtime—labs, and the Chancellor’s £725 million for the next phase of the growth and skills levy will also deliver new digital skills. That package of measures sits alongside the tax reliefs.”
House of Commons16 April 2026Contains Parliamentary information licensed under the Open Parliament Licence v3.0Source ↗
“I am very happy to meet representatives of the VFX industry, including Outpost VFX in my hon. Friend’s constituency. It is worth bearing in mind that there are a whole host of visual effects tax reliefs in place, including a 39% rate on VFX costs, to make it as competitive as possible in this country. I meet regularly and engage with the sector, including the UK Screen Alliance. Protecting our world-leading VFX sector base means ensuring that skills keep pace with artificial intelligence and emerging technologies.”
House of Commons16 April 2026Contains Parliamentary information licensed under the Open Parliament Licence v3.0Source ↗
“We recognise that incidents of undue attention and harassment from the media cause significant distress to the public. We will always defend media freedom, but with this freedom comes big responsibilities. Publishers must operate ethically and within the bounds of the law. The Secretary of State has met families who have experienced press intrusion. We are now carefully considering the next steps to determine how to ensure that public trust and accountability in news media is maintained and improved.”
House of Commons16 April 2026Contains Parliamentary information licensed under the Open Parliament Licence v3.0Source ↗